# KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC

> **NCT04265534** · PHASE2 · TERMINATED · sponsor: **Calithera Biosciences, Inc** · enrollment: 40 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer
- Non-squamous Non-small-cell Lung Cancer
- Non-Squamous Non-Small Cell Neoplasm of Lung
- KEAP1 Gene Mutation
- NRF2 Gene Mutation
- NFE2L2 Gene Mutation

## Interventions

- **DRUG:** Telaglenastat
- **DRUG:** Carboplatin Chemotherapy
- **DRUG:** Pemetrexed Chemotherapy
- **BIOLOGICAL:** Pembrolizumab Immunotherapy
- **DRUG:** Placebo
- **DIETARY_SUPPLEMENT:** Folic acid 400 -1000 μg
- **DIETARY_SUPPLEMENT:** Vitamin B12 1000 μg
- **DRUG:** Dexamethasone 4 mg

## Key facts

- **NCT ID:** NCT04265534
- **Lead sponsor:** Calithera Biosciences, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-24
- **Primary completion:** 2021-11-05
- **Final completion:** 2022-02-09
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Lack of Clinical Benefit
- **Last updated:** 2022-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04265534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04265534, "KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04265534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*